Epilepsy—recurrent, unprovoked seizures—affects approximately 0.6-0.75% of dogs and is the most common neurological disorder in canine practice. Managing epilepsy requires balancing seizure control with treatment side effects and preserving quality of life.
Focal seizures affect one body part or hemisphere, causing localised muscle activity, behavioural changes, or autonomic effects. Generalised tonic-clonic seizures cause full-body convulsions, loss of consciousness, involuntary urination, and post-ictal confusion. Cluster seizures (multiple within 24 hours) and status epilepticus (seizure lasting more than 5 minutes) are emergencies causing hyperthermia, hypoxia, and brain injury if untreated. Each seizure event causes profound distress during the ictus and anxiety during the post-ictal period.
Idiopathic epilepsy (genetic, breed-associated) occurs in otherwise healthy dogs with no identifiable structural brain lesion. Structural epilepsy arises from brain tumours, inflammatory disease, or vascular events. Reactive seizures result from metabolic disturbance (hypoglycaemia, hepatic encephalopathy, toxins). Classification guides investigation and management; MRI and CSF analysis are indicated for dogs presenting with epilepsy, particularly those with atypical age of onset or progressive neurological signs.
First-line antiepileptic drugs (AEDs) in dogs include phenobarbital (highly effective, liver monitoring required) and potassium bromide (effective, long half-life). Second-line options include imepitoin, levetiracetam, and zonisamide. Treatment should be initiated when seizures are frequent, severe, prolonged, or in cluster; all dogs with two or more seizures within 6 months typically benefit from AED therapy. The goal is seizure reduction and improved quality of life—not necessarily complete abolition of all seizures, which may require dose levels causing unacceptable side effects.
Phenobarbital monitoring (serum levels, liver biochemistry every 6 months) prevents toxicity. Common side effects—sedation, polyphagia, polyuria, weight gain—require management and monitoring. Owners should track seizure frequency, duration, and character in a diary app or logbook, enabling objective treatment response assessment. Drug adjustments should be data-driven rather than reactive.
Epileptic dogs and their owners experience significant quality of life impacts—unpredictability of seizures, sleep disruption, anxiety about leaving the dog, and the emotional burden of witnessing seizures. Owner mental health support, access to specialist veterinary neurology, and epilepsy support networks (UK Epilepsy Dogs Facebook group, Canine Epilepsy Support) provide crucial assistance. Validated quality of life tools for epileptic dogs help frame treatment decisions.
All owners of epileptic dogs should have a written emergency plan: when to administer rescue medication (diazepam rectal solution or midazolam buccal gel), when to proceed to emergency veterinary care, and how to manage the post-ictal dog safely. Cluster seizures and status epilepticus require immediate veterinary treatment with IV benzodiazepines and phenobarbital. Reducing time to effective emergency treatment is a critical welfare intervention.